BioSpace News Archive

First Round of Late-Breaking Clinical Trial Results Announced at VIVA22

The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the first of three Late-Breaking Clinical Trials session at the VIVA22 conference, hosted at Wynn Las Vegas.

November 1, 2022
·
11 min read
Biotech Bay

Veracyte Announces Three Abstracts to Be Presented at SITC 2022 Annual Meeting

Veracyte, Inc. announced that three abstracts highlighting the company’s unique, multi-omics immuno-oncology capabilities and offerings will be presented at the Society for Immunotherapy of Cancer’s 37th Annual Meeting & Pre-Conference Programs, taking place November 8-12, 2022, in Boston.

November 1, 2022
·
5 min read
EDAP Announces Focal One® HIFU Reimbursement Raised to Urology APC Level 6 Under CMS Outpatient Prospective Payment System (OPPS) Final Rule for CY23

EDAP TMS SA, the global leader in robotic therapeutic ultrasound, announced that the U.S. Centers for Medicare and Medicaid Services has released its final outpatient prospective payment system reimbursement rule for calendar year 2023, which becomes effective on January 1st.

November 1, 2022
·
3 min read
Genetown

Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - November 01, 2022

Cullinan Oncology, Inc. announced that the compensation committee of the Company’s Board of Directors granted stock option awards to purchase an aggregate of 147,000 shares of its common stock to four employees outside Cullinan Oncology, Inc’s 2021 Stock Option and Incentive Plan.

November 1, 2022
·
2 min read
Business

ViewRay Announces Third Quarter 2022 Results

ViewRay, Inc. announced financial results for the third quarter ended September 30, 2022.

November 1, 2022
·
9 min read
Genetown

Fulcrum Therapeutics® to Participate at Upcoming November 2022 Investor Conferences

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced that management will participate in the following upcoming investor conferences.

November 1, 2022
·
1 min read
Bio NC

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - November 01, 2022

G1 Therapeutics, Inc. announced the grant of inducement stock options exercisable for 5,200 shares of G1’s common stock and 3,400 restricted stock units to one hired employee under the Amended and Restated G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan.

November 1, 2022
·
2 min read
Biotech Beach

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - November 01, 2022

Zentalis™ Pharmaceuticals, Inc. announced that on November 1, 2022, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 350,025 shares of the Company’s common stock to four newly hired employees.

November 1, 2022
·
2 min read
Policy

FDA Roundup: November 1, 2022

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

November 1, 2022
·
3 min read
Business

CSL Enters Licensing Agreement with Arcturus Therapeutics for Next Generation mRNA Vaccine Technology

CSL Limited (ASX:CSL; USOTC:CSLLY) today announces that its subsidiary, CSL Seqirus, has entered into a collaboration and license agreement with Arcturus Therapeutics Holdings Inc (“Arcturus Therapeutics”) to access their late stage self-amplifying mRNA (sa-mRNA) vaccine platform technology.

November 1, 2022
·
8 min read